Research graph
References from Neoadjuvant Immune Checkpoint Inhibitor Therapy in Temporal Bone Squamous Cell Carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
10.1056/nejmoa1805131 · 2018 · External reference
JG. Treatment of unresectable cutaneous squamous cell carcinoma with cemiplimab in a patient on dialysis
2023 · External reference
Use of preoperative immunotherapy in locally advanced unresectable cutaneous squamous cell carcinoma: a case report
10.1159/000540842 · 2024 · External reference
Neoadjuvant cemiplimab followed by radiation for locally advanced, unresectable cutaneous squamous cell carcinoma: a case report
10.1016/j.adro.2024.101529 · 2024 · External reference
Outcomes of treatment with neoadjuvant cemiplimab for patients with advanced, resectable cutaneous squamous cell carcinoma of the head and neck: secondary analysis of a phase 2 clinical trial
10.1001/jamaoto.2023.1729 · 2023 · External reference
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
10.1016/s1470-2045(23)00459-x · 2023 · External reference
Temporal bone resection for lateral skull-base malignancies
10.1007/s11060-020-03445-4 · 2020 · External reference
Temporal bone malignancies
10.1016/j.nec.2012.08.009 · 2013 · External reference
Squamous cell carcinoma of the external auditory canal and temporal bone: an update
10.1007/s12105-018-0908-4 · 2018 · External reference
Squamous cell carcinoma of the temporal bone
10.1002/lary.20937 · 2010 · External reference
Squamous cell carcinoma of the temporal bone: a current review
10.1002/lio2.330 · 2019 · External reference
Neoadjuvant immunotherapy for periauricular cutaneous squamous cell carcinoma
10.1002/hed.70080 · 2026 · External reference
Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma
10.1056/nejmoa2209813 · 2022 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
A radiologist’s guide to response evaluation criteria in solid tumors
10.1067/j.cpradiol.2018.07.016 · 2019 · External reference
Squamous cell carcinoma of the external auditory canal: an evaluation of a staging system
2000 · External reference
Neoadjuvant immunotherapy for head and neck squamous cell carcinoma: expecting its application in temporal bone squamous cell carcinoma
10.1007/s11596-023-2700-2 · 2023 · External reference
Long-term survival after immunotherapy for uncontrolled locally advanced temporal bone squamous cell carcinoma followed by chemoradiotherapy: a case report
10.1002/pro6.1233 · 2024 · External reference
Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and nivolumab
10.3390/jcm7010010 · 2018 · External reference
Temporal bone squamous cell carcinoma: molecular markers involved in carcinogenesis, behavior, and prognosis: a systematic review
10.3390/ijms23094536 · 2022 · External reference
TP53 mutation may underlie increasing incidence of external auditory canal carcinoma
10.1017/s0022215124002159 · 2025 · External reference
Staging proposal for external auditory meatus carcinoma based on preoperative clinical examination and computed tomography findings
10.1177/000348949009900909 · 1990 · External reference
Cancer of the external auditory canal and middle ear in Denmark from 1992 to 2001
10.1002/hed.20877 · 2008 · External reference
Guidelines for treating temporal bone carcinoma based on long-term outcomes
10.1097/mao.0b013e318281e0a9 · 2013 · External reference
Lateral skull base surgery in a pediatric population: a 25-year experience in a referral skull base center
10.1016/j.ijporl.2017.01.017 · 2017 · External reference
State of the art in temporal bone malignancies
10.1097/moo.0000000000000035 · 2014 · External reference
Outcomes of treatment with neoadjuvant cemiplimab for patients with advanced, resectable cutaneous squamous cell carcinoma of the head and neck: secondary analysis of a phase 2 clinical trial
10.1001/jamaoto.2023.1729 · ExternalCitation · doi-reference
Cancer of the external auditory canal and middle ear in Denmark from 1992 to 2001
10.1002/hed.20877 · ExternalCitation · doi-reference
Neoadjuvant immunotherapy for periauricular cutaneous squamous cell carcinoma
10.1002/hed.70080 · ExternalCitation · doi-reference
Squamous cell carcinoma of the temporal bone
10.1002/lary.20937 · ExternalCitation · doi-reference
Squamous cell carcinoma of the temporal bone: a current review
10.1002/lio2.330 · ExternalCitation · doi-reference
Long-term survival after immunotherapy for uncontrolled locally advanced temporal bone squamous cell carcinoma followed by chemoradiotherapy: a case report
10.1002/pro6.1233 · ExternalCitation · doi-reference
Temporal bone resection for lateral skull-base malignancies
10.1007/s11060-020-03445-4 · ExternalCitation · doi-reference
Neoadjuvant immunotherapy for head and neck squamous cell carcinoma: expecting its application in temporal bone squamous cell carcinoma
10.1007/s11596-023-2700-2 · ExternalCitation · doi-reference
Squamous cell carcinoma of the external auditory canal and temporal bone: an update
10.1007/s12105-018-0908-4 · ExternalCitation · doi-reference
Neoadjuvant cemiplimab followed by radiation for locally advanced, unresectable cutaneous squamous cell carcinoma: a case report
10.1016/j.adro.2024.101529 · ExternalCitation · doi-reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · ExternalCitation · doi-reference
Lateral skull base surgery in a pediatric population: a 25-year experience in a referral skull base center
10.1016/j.ijporl.2017.01.017 · ExternalCitation · doi-reference
Temporal bone malignancies
10.1016/j.nec.2012.08.009 · ExternalCitation · doi-reference
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
10.1016/s1470-2045(23)00459-x · ExternalCitation · doi-reference
TP53 mutation may underlie increasing incidence of external auditory canal carcinoma
10.1017/s0022215124002159 · ExternalCitation · doi-reference
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
10.1056/nejmoa1805131 · ExternalCitation · doi-reference
Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma
10.1056/nejmoa2209813 · ExternalCitation · doi-reference
A radiologist’s guide to response evaluation criteria in solid tumors
10.1067/j.cpradiol.2018.07.016 · ExternalCitation · doi-reference
Guidelines for treating temporal bone carcinoma based on long-term outcomes
10.1097/mao.0b013e318281e0a9 · ExternalCitation · doi-reference
State of the art in temporal bone malignancies
10.1097/moo.0000000000000035 · ExternalCitation · doi-reference
Use of preoperative immunotherapy in locally advanced unresectable cutaneous squamous cell carcinoma: a case report
10.1159/000540842 · ExternalCitation · doi-reference
Staging proposal for external auditory meatus carcinoma based on preoperative clinical examination and computed tomography findings
10.1177/000348949009900909 · ExternalCitation · doi-reference
Temporal bone squamous cell carcinoma: molecular markers involved in carcinogenesis, behavior, and prognosis: a systematic review
10.3390/ijms23094536 · ExternalCitation · doi-reference
Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and nivolumab
10.3390/jcm7010010 · ExternalCitation · doi-reference
